Hypoxic Red Blood Cells in Sickle Cell Anemia
NCT: NCT06743113 · NOT_YET_RECRUITING
NCT IDNCT06743113
StatusNOT_YET_RECRUITING
Start Date2026-09
Completion2029-10
SponsorHemanext (INDUSTRY)
First posted
Last updated
Brief Summary
The overall objective of this study is to evaluate the effectiveness and safety of transfusing hypoxic red blood cells manufactured with the Hemanext ONE system in patients with sickle cell anemia. The Hemanext ONE device was cleared through the De Novo process in September 2023.
Frequently Asked Questions
What is Hypoxic Red Blood Cells in Sickle Cell Anemia?
Hypoxic Red Blood Cells in Sickle Cell Anemia is a clinical trial registered under NCT06743113. Current status: NOT_YET_RECRUITING.
What is the status of NCT06743113?
The current status of NCT06743113 (Hypoxic Red Blood Cells in Sickle Cell Anemia) is: NOT_YET_RECRUITING.
When did Hypoxic Red Blood Cells in Sickle Cell Anemia start?
Hypoxic Red Blood Cells in Sickle Cell Anemia started on 2026-09.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.